Reported 19 days ago
Bristol-Myers Squibb (BMY), a leading global pharmaceutical company, is known for its robust growth pipeline in areas like oncology and cardiology. The company aims to expand its portfolio with new product launches and strategic partnerships while navigating the challenges posed by the decline of older drugs. With anticipated earnings well above its current dividend of $2.48 and a dividend yield of 5.64%, BMY is well-positioned to maintain and potentially grow its high-yield dividend, having increased it consistently for 16 years.
Source: YAHOO